Late Stage Failures, Whose to Blame?

August 2010
Pharmaceutical Representative;Aug2010, Vol. 40 Issue 8, p9
The article reports that Pfizer Inc.'s Mylotang has been cancelled after its Phase II trial shows that it increases death rate for patients with Leukemia in the U.S.


Related Articles

  • Pfizer Pulls Leukemia Treatment. Koroneos, George // Pharmaceutical Executive;Jul2010, Vol. 30 Issue 7, p19 

    The article reports on the decision of pharmaceutical company Pfizer Inc. to stop production of the leukemia-treating drug Myoltarg.

  • Long-Awaited Torcetrapib Will Not Be Released, Too Risky. Elliott, William T. // Internal Medicine Alert;5/15/2007, Vol. 29 Issue 9, p1 

    The article reports on the decision of Pfizer to discontinue the development of torcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor that has been in development for about 15 years, following a trial which showed an increase in death from all causes associated with the drug.

  • A PILL TO CURE CANCER? Skloot, Rebecca // Popular Science;Jul2001, Vol. 259 Issue 1, p40 

    Reports on the development of an experimental drug called Gleevec tested to cure chronic myeloid leukemia (CML). Description of blast crisis in patients with CML; Cost of the drug; Reason for the popularity of the drug; Causes of CML; Physician who developed the drug.

  • PHARMA: CLINIC ROUNDUP.  // BioWorld Today;1/10/2014, Vol. 25 Issue 7, p14 

    The article reports on the exclusive collaborative drug development agreement between Avillon Group and Pfizer Inc.

  • SuperGen acquires European marketing rights for Nipent.  // PharmaWatch: Cancer;April 2004, Vol. 3 Issue 4, p7 

    Reports that SuperGen has acquired the European marketing rights from Pfizer to the anticancer compound Nipent (pentostatin for injection), an approved single-treatment for patients with hairy cell leukemia. SuperGen's clinical studies for the use of Nipent as a treatment for several...

  • Leukemia Drug Heralds Molecularly Targeted Era. Vastag, Brian // JNCI: Journal of the National Cancer Institute;01/05/2000, Vol. 92 Issue 1, p6 

    Introduces STI-571, a drug that selectively targets chronic myelogenous leukemia cells without any of the traditional chemotherapy side effects. Information on its development; Comments on the drug; Results of clinical trials.

  • Postremission therapy in older adults with acute myeloid leukemia: an opportunity for new drug development. Schiffer, C.A. // Leukemia (08876924);Apr2002, Vol. 16 Issue 4, p745 

    Discusses opportunities for drug development presented by postremission therapy in older adults with acute myeloid leukemia. Key issues of interest; Analysis of pertinent topics and relevant issues; Implications on the study of leukemia.

  • Pfizer and Lilly shoulder novel pain-drug risks. Sinha, Gunjan // Nature Biotechnology;Jan2014, Vol. 32 Issue 1, p9 

    The article reports on the deal between pharmaceutical companies New York-based Pfizer and Eli Lilly & Co. in Indianapolis, Indiana in October 2013 for the development of the former's anti-nerve growth factor drug known as tanezumab.

  • Pfizer Backs Out of Opioid Deal with Adolor.  // Bioworld Week;12/27/2010, Vol. 18 Issue 52, p4 

    The article reports on the withdrawal of the New York-based Pfizer Inc. from its deal with Adolor Corp. of Exton, Pennsylvania.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics